Caliber Imaging & Diagnostics

Executive Summary

Caliber Imaging & Diagnostics (Caliber I.D.) is a medical device company specializing in non-invasive, real-time cellular-level imaging through its proprietary reflectance confocal microscopy (RCM) technology, commercialized under the VivaScope brand. The VivaScope system provides high-resolution, in vivo images of skin and other tissues, enabling clinicians to identify suspicious lesions and guide biopsies without the need for surgical excision. Its primary application is in dermatology for the early detection and management of skin cancers, including melanoma, where it offers a significant reduction in unnecessary biopsies and improved diagnostic accuracy. Caliber I.D. has established a foothold in the U.S. and European markets, with its technology being adopted by leading dermatology practices and research institutions. The company operates in a growing market for non-invasive diagnostics, driven by increasing skin cancer incidence and demand for precision medicine. While RCM is recognized for its clinical benefits, adoption faces barriers including high device costs, limited reimbursement coverage outside specific indications, and need for specialized training. Caliber I.D. is focusing on expanding reimbursement codes, developing new applications (e.g., oral mucosa and surgical margins), and enhancing its software with AI-assisted diagnostics. With a solid technology platform and a clear value proposition, the company is well-positioned for growth, though execution on commercial expansion and regulatory clearances remains critical. We assign a conviction score of 60 out of 100, reflecting strong technology but moderate near-term catalysts.

Upcoming Catalysts (preview)

• Q1 2027FDA Clearance for VivaScope in New Indication (e.g., Oral Mucosa)50% success
• Q4 2026Strategic Partnership for Commercial Expansion (e.g., with Large Derm Practice or Distributor)60% success
• Q2 2027Release of Next-Generation VivaScope System with Enhanced AI Features40% success